EP1888028A1 - Forme posologique de presentation pharmaceutique agissant sur la microcirculation et contenant au moins un flavonoide - Google Patents

Forme posologique de presentation pharmaceutique agissant sur la microcirculation et contenant au moins un flavonoide

Info

Publication number
EP1888028A1
EP1888028A1 EP06700942A EP06700942A EP1888028A1 EP 1888028 A1 EP1888028 A1 EP 1888028A1 EP 06700942 A EP06700942 A EP 06700942A EP 06700942 A EP06700942 A EP 06700942A EP 1888028 A1 EP1888028 A1 EP 1888028A1
Authority
EP
European Patent Office
Prior art keywords
dose
active ingredient
mixture according
active
ingredient mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06700942A
Other languages
German (de)
English (en)
Inventor
Hermine Engl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1888028A1 publication Critical patent/EP1888028A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Definitions

  • the invention relates to an active ingredient mixture, in particular active ingredient mixture for the preventive health sector, comprising at least one active ingredient, which is present in powdery and / or granulated form and / or as mother tincture and / or as pure substance and / or as extract, from the group of capillary-active, microcirculatory effective phytopharmacological agents, preferably a flavonoid and / or a modified flavonoid.
  • the invention relates to a method for producing a drug mixture.
  • a special group of phytopharmaceuticals are flavonoids.
  • Therapeutic compositions are known, for example, from EP 0 417 209 B1.
  • the object of the invention is to provide a drug mixture which avoids the one hand, the above health disadvantages and on the other hand as a preventive means, for example as a drink or as a functional drink or as a dragee, before long or long trips, such as long-haul flights, but also train -, bus or car travel or sedentary activity can be taken to prevent impairment of physical well-being or possible health venous damage.
  • a preventive means for example as a drink or as a functional drink or as a dragee, before long or long trips, such as long-haul flights, but also train -, bus or car travel or sedentary activity can be taken to prevent impairment of physical well-being or possible health venous damage.
  • Diosmin with a dose of 0.1 to 600 mg, preferably 1, 5 to 300 mg, in particular 5 to 30 mg,
  • Gingko at a dose of from 0.1 to 120 mg, preferably from 1.5 to 100 mg, in particular from 5 to 30 mg,
  • Vitis viniferae red vine leaves at a dose of 0.1 to 720 mg, preferably
  • the invention it is for the first time possible to counteract the formation of free radicals and inflammatory mediators by administration of the active substance, preferably in liquid administration.
  • the prevention or prophylaxis serves to ensure that there are no above-mentioned problems, especially with long-term travel.
  • the active compound mixture according to the invention as a functional beverage provides optimum protection against possibly occurring congestive consequences of the blood flow.
  • noticeable effects of an incipient functional impairment on the general well-being are fatigue, fatigue, dizziness in the head; Loss of intellectual capacity and also an uncomfortable feeling of heaviness in the legs.
  • Travel thrombosis can be prevented in addition to conscious fluid intake by appropriate regular physical exercise.
  • Sufficient fluid intake serves to favor the physiological blood flow. If the active ingredient according to the invention is administered, this provides relief for the congestion problem during long journeys.
  • a preventive measure against complaints outlined above takes place by the, preferably continuous, oral intake, for example drinking the drink solution according to the invention, shortly before the trip and especially during the journey or during the sitting activity.
  • aescin and / or water-soluble or micronized flavonoids such as rutin and / or rutoside and / or diosmin and / or hamamelis and / or ginkgo and / or hesperidin and / or red vine leaves and / or Ruscus aculeatus (butcher's broom).
  • vascular active agents from the plant area protect vascular structures from harmful influences, as they
  • Aescin for example, simultaneously tones the vessels. Furthermore, Aescin lowers or regulates pathologically increased vascular permeability and counteracts the formation of edema.
  • Rutin or rutoside is readily soluble in water. It reduces capillary permeability, thereby reducing the permeation of macromolecules and thus reducing the accumulation of water in the connective tissue.
  • diosmin and hesperidin lead to a strengthening of venous capacity and toning and, on the other hand, reduce pathologically increased capillary permeability and an increase in capillary resistance.
  • Gingocofiavonglycosides obtained from gingko biloba leaves, have a multifactorial effect on the impaired functional unit of blood-vessel tissue. It improves microcirculation and fluidity of the blood as a result of lowering the blood flow
  • Blood viscosity Also beneficial is an increase in RBC flexibility, a reduction in the tendency for RBC aggregation, inhibition of platelet aggregation, and an increase in blood flow velocity. In addition, the burden-induced leucocyte accumulation and vascular adherence is reduced. The increased capillary permeability is reduced.
  • the active ingredient quercetin or isoquercitrin, contained in the extract of the red vine leaves, provides protection of the vascular epithelium by stabilizing the membranes and increasing elasticity. There is a normalization of vascular permeability. As a result, there is a reduced extravasation of plasma, proteins or water into the vessel surrounding interstitial tissue, as with all these vasoactive phytopharmaceuticals.
  • the Ruscus aculeatus (mouse dome) has the above-mentioned positive properties.
  • At least one vitamin such as, for example, ascorbic acid
  • the active ingredient is admixed with a preferably water-soluble vitamin, for example ascorbic acid.
  • the addition of vitamin C allows the antioxidant mechanism to catalyze metabolism.
  • At least citric acid and / or salts thereof are contained at a dose of 1 to 10 g, preferably 4 to 6 g.
  • this addition is certainly beneficial.
  • At least one flavoring agent is contained at a dose of 0.1 to 20 g / l. It can not be denied that a consumer's liking better positions the drink solution on the market.
  • At least one flavoring in particular a natural flavoring, such as lemon, lime, blackcurrant, blueberry, cherry, orange, Mandarin, Grapefruit, Almond, Pineapple, Blue Grape, White Grape Juice.
  • a natural flavoring such as lemon, lime, blackcurrant, blueberry, cherry, orange, Mandarin, Grapefruit, Almond, Pineapple, Blue Grape, White Grape Juice.
  • Elderberry, strawberry, sea-buckthorn flavor or citrus flavoring with a dose of 50 to 1,000mg, preferably 200 to 700mg.
  • at least one additive preferably a silicate or a silicon dioxide and / or a binder, such as cellulose fibers included. An improvement in the consistency is to be expected from these additives.
  • At least one trace element or mineral substance such as magnesium, calcium, potassium or sodium, with a dose of 10 to 2,000 mg, preferably 200 to 500 mg, contained.
  • the substance mixture is enhanced in its qualitative effectiveness.
  • At least one amino acid is contained at a dose of 0.01 to 200 mg, preferably 1 to 20 mg.
  • Amino acids play an important role in nutritional science, so that their addition is certainly beneficial.
  • At least one food colorant in particular a natural food colorant, such as, for example, quinoline yellow, beta carotene or yellow-orange "S", is of course an appealing visual impression of the drink solution for a certain market conquest of invaluable advantage.
  • a natural food colorant such as, for example, quinoline yellow, beta carotene or yellow-orange "S”
  • At least one sweetener such as saccharin sodium, sodium cyclamate, glucose, glucose, aspartame, dextrose, maltodextrin, sorbitol, xylitol, acesulfame, cane sugar, inulin or fructose, is included.
  • saccharin sodium, sodium cyclamate glucose, glucose, aspartame, dextrose, maltodextrin, sorbitol, xylitol, acesulfame, cane sugar, inulin or fructose
  • At least one active ingredient according to claim 1 is included at a dose that meets the requirements of a dietary supplement. Due to the indicated dosage of the individual active ingredients, this beverage can be positioned on the consumer goods market as a dietary supplement.
  • the requirements of a food supplement are in the sense of veno-donating, blood flow supporting, the prevention of venous congestion serving, edema-protective, edema-reducing and / or vascular sealing and / or endothelium stabilizing and / or anti-inflammatory and / or antioxidant (antiaging) properties to see so that due especially at Long-haul flights and similar loads, such as long trips of all kinds, with appropriate sedentary activity, special physical stress (military, surgery), in competitive sports and / or mental stress support in terms of venous blood flow improvement is offered.
  • the finished product is as extract mixture and / or as a functional beverage and / or dragee (s) and / or as a tablet (s) and / or as granules and / or as effervescent powder and / or syrup and / or as a drinking concentrate and / or as Aufschwemmains and / or as chewing gum and / or as a two-phase pack before.
  • the active ingredient mixture according to the invention in whatever composition, does not limit any of the possible administration forms.
  • Each dosage form has its positive sides. For example, dragees are more space-saving than bottled drinking solutions. On the other hand, however, drinking solutions contribute again to the balance of the fluid balance. So it can be chosen the most appropriate form.
  • an alcoholic or alcohol-free solvent for example water, fruit juice, tea, mineral water o. The like. Used for the finished product as a solvent.
  • it could be offered as a non-alcoholic wellness drink and / or functional nutritional supplement.
  • This drink is therefore ideal as a preventative travel drink for long-term travelers, as for long-haul flights or long train rides. It prevents vascular changes in the microcirculation area and thus those venous congestions that are as well as a factor in the development of travel thrombosis.
  • At least one homeopathic agent for example Lachesis and / or arnica and / or escin and / or rutin and / or rutoside and / or diosmin and / or hamamelis and / or gingko and / or hesperidin and or red vine leaves , contain.
  • the use of these homeopathic remedies helps to increase the body's defense.
  • At least one of the active substances aescin and / or rutoside and / or diosmin and / or gingko and / or hesperidin and / or red vine leaves is admixed in homeopathic form in aqueous solution in the dose C20 to C40, preferably C30, especially D6 to D30.
  • the use of these homeopathic remedies increases the body's defense.
  • witch hazel is included as an admixture in homeopathic form in aqueous solution in the dose D6 to D12.
  • Hamamelis has anti-inflammatory, antioxidant and antiallergic properties. All of these properties increase the well-being of humans, especially in stressful situations.
  • At least one liquid stabilizer such as nitrogen or carbon dioxide is introduced into the drinking solution.
  • Nitrogen is used in a laminate-coated container, wherein a nitrogen blanketing and pressure neutrality is provided. When nitrogen is injected, an overpressure of 0.5 to 1 bar is provided.
  • the advantage of nitrogen is that it reduces the oxygen content, which improves the shelf life of the vitamins.
  • carbon dioxide could also be used. It will bring about 0, 1 to 5.5 g / l, preferably 2-3 g / l bring.
  • a preservative is included.
  • the durability can be selected or extended accordingly.
  • the object of the invention is also to provide a process for preparing a drug mixture that can be taken preventively as a drink or as a functional beverage before long or long trips, such as long-haul flights, but also train, bus or car trips or sedentary activity. to prevent impairment of physical well-being or possible venous injuries.
  • the process according to the invention is characterized in that at least one active substance according to claim 1 is admixed with at least one further additional substance according to the above claims, for example a mineral and / or a vitamin, and that this mixture, in particular this powder mixture, preferably immediately before ingestion, in a solvent, in particular in an alcoholic and / or alcohol-free solvent, for example water, fruit juice or tea, in solution or to a suspension suspension and / or to a true solution.
  • a solvent in particular in an alcoholic and / or alcohol-free solvent, for example water, fruit juice or tea
  • This drink solution prevents swelling and inflammation and helps to improve the blood flow microcirculatory.
  • Fluid stabilization overlay with nitrogen This hydration solution prevents swelling and inflammation and also improves microcirculation.
  • the flavor of the pineapple aroma comes into its own and has a fruity appearance.
  • Flavor 1 g lemon flavor
  • Sweetener acesulfame corresponding to 5 g of sugar
  • This drink solution prevents swelling and inflammation and contributes to
  • Active substance 600 mg of rutoside in the form of troxerutin
  • This drink solution prevents swelling and inflammation, helps to improve microcirculation.
  • Raspberry active ingredient 120 mg hesperidin
  • This drinking solution increases the protection against swelling and also protects against inflammation.
  • Active ingredient 500 mg red vine leaves.
  • Other substances 200 mg magnesium
  • Flavor 2.5 g cherry or tangerine flavor
  • Sweetener Cane sugar equivalent to 5 g of sugar
  • Examples 7 and 8 are drug mixtures which may optionally be marketed as nutritional supplements.
  • the requirements of a dietary enterality are in the sense of veno-antagonizing, oestusting, edema-protective, edema-reducing and / or vascular-occlusive, venous congestion-inhibiting and / or or to see endothelial stabilizing and / or anti-inflammatory and / or antioxidative (antiaging) properties
  • Traveling thrombosis prophylaxis is medically recommended not only for people with moderate and severe risk of thrombosis, but also for people with a low or apparently largely healthy vascular system.
  • the circulatory system in particular the leg vein system is loaded by
  • Drinking solutions distributed throughout the day about 1 1/2 liters in total.

Abstract

L'invention concerne un mélange de matières actives, en particulier un mélange de matières actives utilisées dans le domaine de la santé préventive, comprenant au moins un agent actif, qui se présente sous forme de poudre et/ou de granules et/ou une prétrituration et/ou une substance pure et/ou un extrait. Ledit agent actif provient du groupe d'agents actifs phytopharmacologiques, agissant sur les capillaires, et présentant une action sur la microcirculation, de préférence un flavonoïde et/ou un flavonoïde modifié. L'aescine, le rutoside, la troxérutine, la diosmine, l'hespéridine, le ginkgo, des treilles rouges (Vitis viniferae), et le petit houx (Ruscus aculeatus) sont utilisés comme agent actif. Dans le mélange d'agents actifs de l'invention, une vitamine, un produit aromatique et un oligoélément ou un sel minéral et un additif sont utilisés.
EP06700942A 2005-01-14 2006-01-13 Forme posologique de presentation pharmaceutique agissant sur la microcirculation et contenant au moins un flavonoide Withdrawn EP1888028A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT552005A AT501682A1 (de) 2005-01-14 2005-01-14 Verfahren zur herstellung einer wirkstoffmischung
PCT/AT2006/000015 WO2006089317A1 (fr) 2005-01-14 2006-01-13 Forme posologique de presentation pharmaceutique agissant sur la microcirculation et contenant au moins un flavonoide

Publications (1)

Publication Number Publication Date
EP1888028A1 true EP1888028A1 (fr) 2008-02-20

Family

ID=36424571

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06700942A Withdrawn EP1888028A1 (fr) 2005-01-14 2006-01-13 Forme posologique de presentation pharmaceutique agissant sur la microcirculation et contenant au moins un flavonoide

Country Status (3)

Country Link
EP (1) EP1888028A1 (fr)
AT (1) AT501682A1 (fr)
WO (1) WO2006089317A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1949801A1 (fr) * 2006-11-17 2008-07-30 Maria Ascension Fernandez Jimenez Boisson nutritive et régénératrice
EP2353596A1 (fr) * 2010-02-02 2011-08-10 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition combinée comprenant en tant que principes actifs de la L-carnitine ou de la propionyl L-carnitine pour la prévention d'une insuffisance veineuse chronique
ITRM20120591A1 (it) * 2012-11-26 2014-05-27 Ambiotec Sas Di Ammendola Sergio Composizioni da utilizzare nelle flebopatologie da stasi ed infiammatorie
FR3075602B1 (fr) * 2017-12-21 2020-06-12 Urgo Recherche Innovation Et Developpement Produit de combinaison pour la prevention et le traitement des insuffisances veineuses chroniques
DE102021102101A1 (de) 2020-01-31 2021-08-05 Humanicon GmbH 2-Phasen-Präparat für Reisen
DE202020100539U1 (de) 2020-01-31 2021-02-22 Humanicon GmbH 2-Phasen-Präparat für Reisen

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346638A1 (de) 1983-12-23 1985-07-04 Cassella Ag, 6000 Frankfurt Photostabilisierung von molsidomin
ATE160939T1 (de) 1988-09-19 1997-12-15 Oxycal Lab Inc Zusammensetzungen und verabreichungsverfahren für heilmittel
DE3940094A1 (de) 1989-12-04 1991-06-06 Montana Ltd Wirkstoffkonzentrate und neue wirkstoff-kombinationen aus blaettern von ginkgo biloba, ein verfahren zu ihrer herstellung und die wirkstoff-konzentrate bzw. die wirkstoff-kombinationen enthaltenden arzneimittel
WO1992015315A1 (fr) 1991-03-06 1992-09-17 Wilkinson Alfred H B Mode de traitement de l'herpes
DE4201179A1 (de) 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
FR2726469B1 (fr) 1994-11-08 1996-12-13 Adir Composition pharmaceutique pour l'administration orale de flavonoides
US6054128A (en) * 1997-09-29 2000-04-25 Wakat; Diane Dietary supplements for the cardiovascular system
IT1296920B1 (it) 1997-12-04 1999-08-03 Indena Spa Uso di complessi di estratti vitis vinifera con fosfolipidi come agenti anti-aterosclerotici
JP4295840B2 (ja) * 1997-12-09 2009-07-15 株式会社林原生物化学研究所 血行改善剤
US6030621A (en) 1998-03-19 2000-02-29 De Long; Xie Ginkgo biloba composition, method to prepare the same and uses thereof
US20040072765A1 (en) * 1999-04-28 2004-04-15 Novogen Research Pty Ltd. Cardiovascular and bone treatment using isoflavones
ATE322904T1 (de) 2000-05-25 2006-04-15 Boehringer Ingelheim Int Zusammensetzung zum verbesserten zellenschutz welche ein lipophiles antioxydans sowie ein hydrophilen antioxidans enthält
CN1109681C (zh) * 2000-06-15 2003-05-28 宁夏大学 黄酮铬及其生产方法和用途
DE50101673D1 (de) 2000-08-17 2004-04-15 Medichemie Ag Ettingen Verwendung von extrakten aus ginkgo biloba-blättern zur traumprovokation
DE10122714A1 (de) 2001-05-10 2002-11-21 Brench Ag Verwendung von Rutinen und Aescinen zur Behandlung okulärer Durchblutungsstörungen
FR2828492B1 (fr) * 2001-08-07 2003-10-17 Nexans Composition a haute resistance a la propagation du feu
US6753325B2 (en) 2001-11-06 2004-06-22 The Quigley Corporation Composition and method for prevention, reduction and treatment of radiation dermatitis
US7083813B2 (en) * 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
DE10315022A1 (de) 2003-03-03 2004-09-23 Bioplanta Arzneimittel Gmbh Verwendung von Rutin und Isorhamnetin zur Behandlung von depressiven Verstimmungen und Erkrankungen sowie bei anderen affektiven Störungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006089317A1 *

Also Published As

Publication number Publication date
AT501682A1 (de) 2006-10-15
WO2006089317A1 (fr) 2006-08-31

Similar Documents

Publication Publication Date Title
US6436446B1 (en) Composition for increasing bone density
ES2329370T3 (es) Bebida para el control del peso.
JP4166951B2 (ja) 脳性および加齢性疾患の予防または治療のためのカルニチンおよびレスベラトロールの組み合わせ
EP0405930A2 (fr) Suspension pharmaceutique aqueuse pour des agents actifs pharmaceutiques essentiellement insolubles dans l'eau
DE3435040A1 (de) Pharmazeutische zusammensetzung, geeignet zur behandlung von hang-over-symptomen
EP1888028A1 (fr) Forme posologique de presentation pharmaceutique agissant sur la microcirculation et contenant au moins un flavonoide
JP2818220B2 (ja) 食品用の含水有機溶剤抽出物含有組成物および医薬用の含水有機溶剤抽出物含有組成物、並びにそれらの製造方法
DE69913116T2 (de) Orale flüssige lösung enthaltend das antidepressivum mirtazapine
JP2002233331A (ja) 血行障害の改善作用を有する健康補助食品
DE3319575C2 (fr)
GB2282967A (en) Compositions containing fructose and plant extracts
JP2003231647A (ja) 内服液組成物
US20050181083A1 (en) Diet food product
JP2003535120A (ja) 低炭水化物組成物、そのキット、及びその使用方法
DE19502789A1 (de) Arzneimittel
AT501221A1 (de) Wirkstoffmischung
EP2269649A2 (fr) Compositions contenant un system actif capillaire a differentiabilite d'application et utilisation
JP2004175672A (ja) グリチルリチン酸含有経口用液剤
KR20010009653A (ko) 성기능 장애를 위한 치료용 조성물
JPH0473411B2 (fr)
KR20150128157A (ko) 맛이 차폐된 비타민 c 과립
EP3646861B1 (fr) Composition hypotensive comprenant des nitrates, cafféine et sulforaphane
RU2737242C1 (ru) Натуральный энергетический продукт
EP1309335B1 (fr) Utilisation d'extraits de feuilles de ginkgo biloba pour susciter des reves
DE19837790A1 (de) Verfahren zum Erzeugen von Mitteln zum Behandeln des menschlichen Körpers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070809

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR

RAX Requested extension states of the european patent have changed

Extension state: HR

Payment date: 20070808

RTI1 Title (correction)

Free format text: PHARMACEUTICAL DOSAGE FORM EFFECTIVE AT MICROCIRCULATORY LEVEL CONTAINING AT LEAST ONE FLAVONOID

17Q First examination report despatched

Effective date: 20080918

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120801